The latest news and insights from across the industry
Leverage software built by a team with world- class scientific, engineering and industry credentials.
It's clear to me that healthcare systems globally – and in the US – will continue to ramp up their scrutiny of the value proposition for new medical technologies. EntityRisk's tools are emerging at just the right time to help companies and patients understand that value.Jeffrey B. KindlerEntityRisk Board of Directors
Healthcare industry leaders, including CFOs, face increased risk when launching new drugs, ranging from challenges in drug pricing and access related to uncertainty in real-world effectiveness, utilization and value.Frank D'AmelioEntityRisk Board of Directors
If a biopharma board isn’t asking ‘how vulnerable are we going to be to policy developments in the U.S. in the next five years,’ then they’re not doing their job. They’re asking many more questions than they were even two or three years ago.Neal MasiaEntityRisk CEO
Given its tools, healthcare experience and thought leadership, EntityRisk is well positioned to help leaders mitigate this uncertainty, assess, develop and manage outcomes-based contracts and continue to propel healthcare transformation.Frank D'AmelioEntityRisk Board of Directors